FOLD News and Press, Amicus Therapeutics Inc. From 10/01/18

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, September 28 . Bullish Calls Groupon (GRPN): Cramer had recommended a buy at $4, and it has come down since. He is still behind the stock, as the company has a strong balance sheet and is doing we...

Shares in Amicus ( FOLD ) are down ~30% since I penned my introductory article, Is Amicus On The Verge Of A Breakout? . Clearly, my timing was off as the answer was "no". However, not much has changed in Amicus since the article. While there have been a couple of hiccups, the fundamental th...

NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow Jones Industrial Average dropped 0.4 percent to close at 26,385.28, while the S&P 500 ...

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...

CRANBURY, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New...

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ocean Power Technologies, Inc. (NASDAQ:OPTT), Amicus Therapeutics, Inc. ...

Amicus Therapeutics (NASDAQ: FOLD ) signs a definitive agreement in which it will receive worldwide development and commercial rights for ten gene therapy programs developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State...

License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases ...